“Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives
The pharmaceutical industry faces unsustainable program failure despite significant increases in investment. Dwindling discovery pipelines, rapidly expanding R&D budgets and increasing regulatory control, predict significant gaps in the future drug markets. The cumulative duration of discove...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-09-01
|
| Series: | Proteomes |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2227-7382/4/3/28 |
| _version_ | 1818035116921847808 |
|---|---|
| author | Holly Matthews James Hanison Niroshini Nirmalan |
| author_facet | Holly Matthews James Hanison Niroshini Nirmalan |
| author_sort | Holly Matthews |
| collection | DOAJ |
| description | The pharmaceutical industry faces unsustainable program failure despite significant increases in investment. Dwindling discovery pipelines, rapidly expanding R&D budgets and increasing regulatory control, predict significant gaps in the future drug markets. The cumulative duration of discovery from concept to commercialisation is unacceptably lengthy, and adds to the deepening crisis. Existing animal models predicting clinical translations are simplistic, highly reductionist and, therefore, not fit for purpose. The catastrophic consequences of ever-increasing attrition rates are most likely to be felt in the developing world, where resistance acquisition by killer diseases like malaria, tuberculosis and HIV have paced far ahead of new drug discovery. The coming of age of Omics-based applications makes available a formidable technological resource to further expand our knowledge of the complexities of human disease. The standardisation, analysis and comprehensive collation of the “data-heavy” outputs of these sciences are indeed challenging. A renewed focus on increasing reproducibility by understanding inherent biological, methodological, technical and analytical variables is crucial if reliable and useful inferences with potential for translation are to be achieved. The individual Omics sciences—genomics, transcriptomics, proteomics and metabolomics—have the singular advantage of being complimentary for cross validation, and together could potentially enable a much-needed systems biology perspective of the perturbations underlying disease processes. If current adverse trends are to be reversed, it is imperative that a shift in the R&D focus from speed to quality is achieved. In this review, we discuss the potential implications of recent Omics-based advances for the drug development process. |
| first_indexed | 2024-12-10T06:49:57Z |
| format | Article |
| id | doaj.art-4fabaf2091d0453faf2f631095fdc1ff |
| institution | Directory Open Access Journal |
| issn | 2227-7382 |
| language | English |
| last_indexed | 2024-12-10T06:49:57Z |
| publishDate | 2016-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Proteomes |
| spelling | doaj.art-4fabaf2091d0453faf2f631095fdc1ff2022-12-22T01:58:34ZengMDPI AGProteomes2227-73822016-09-01432810.3390/proteomes4030028proteomes4030028“Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future PerspectivesHolly Matthews0James Hanison1Niroshini Nirmalan2Department of Life Sciences, Faculty of Natural Sciences, Imperial College, London SW7 2AZ, UKManchester Royal Infirmary, Oxford Road, Greater Manchester M13 9WL, UKEnvironment and Life Sciences, University of Salford, Greater Manchester M5 4WT, UKThe pharmaceutical industry faces unsustainable program failure despite significant increases in investment. Dwindling discovery pipelines, rapidly expanding R&D budgets and increasing regulatory control, predict significant gaps in the future drug markets. The cumulative duration of discovery from concept to commercialisation is unacceptably lengthy, and adds to the deepening crisis. Existing animal models predicting clinical translations are simplistic, highly reductionist and, therefore, not fit for purpose. The catastrophic consequences of ever-increasing attrition rates are most likely to be felt in the developing world, where resistance acquisition by killer diseases like malaria, tuberculosis and HIV have paced far ahead of new drug discovery. The coming of age of Omics-based applications makes available a formidable technological resource to further expand our knowledge of the complexities of human disease. The standardisation, analysis and comprehensive collation of the “data-heavy” outputs of these sciences are indeed challenging. A renewed focus on increasing reproducibility by understanding inherent biological, methodological, technical and analytical variables is crucial if reliable and useful inferences with potential for translation are to be achieved. The individual Omics sciences—genomics, transcriptomics, proteomics and metabolomics—have the singular advantage of being complimentary for cross validation, and together could potentially enable a much-needed systems biology perspective of the perturbations underlying disease processes. If current adverse trends are to be reversed, it is imperative that a shift in the R&D focus from speed to quality is achieved. In this review, we discuss the potential implications of recent Omics-based advances for the drug development process.http://www.mdpi.com/2227-7382/4/3/28drug discoveryomicsgenomicsproteomicsmetabolomics |
| spellingShingle | Holly Matthews James Hanison Niroshini Nirmalan “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives Proteomes drug discovery omics genomics proteomics metabolomics |
| title | “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives |
| title_full | “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives |
| title_fullStr | “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives |
| title_full_unstemmed | “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives |
| title_short | “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives |
| title_sort | omics informed drug and biomarker discovery opportunities challenges and future perspectives |
| topic | drug discovery omics genomics proteomics metabolomics |
| url | http://www.mdpi.com/2227-7382/4/3/28 |
| work_keys_str_mv | AT hollymatthews omicsinformeddrugandbiomarkerdiscoveryopportunitieschallengesandfutureperspectives AT jameshanison omicsinformeddrugandbiomarkerdiscoveryopportunitieschallengesandfutureperspectives AT niroshininirmalan omicsinformeddrugandbiomarkerdiscoveryopportunitieschallengesandfutureperspectives |